Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 315-323

  Jia, Yitao ^a   Liu, Min ^a   Huang, Wangang ^b   Wang, Zhenbao ^b   He, Yutong ^c   Wu, Jianhua ^b   Ren, Shuguang ^b   Ju, Yingchao ^b   Geng, Ruichao ^b   Li, Zhongxin ^b  

^a HEBEI GENERAL HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Cancer Institute of Hebei Province   (China)

Author keywords

Angiogenesis; Colorectal cancer; Lymphangiogenesis; Metastasis; Recombinant human endostatin

Indexed keywords

RECOMBINANT ENDOSTATIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; IMMUNOBLOTTING; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; ENDOSTATINS; FLOW CYTOMETRY; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863471211     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9447-y     Document Type: Article

References (37)

1. Center MM, Jemal A, Ward E (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 6:1688-1694
2. Becouarn Y, Rougier P (1998) Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 25(2 Suppl 5):23-31
3. Ng M, Roy-Chowdhury S, Lum SS, Morgan JW, Wong JH (2009) The impact of the ratio of positive to total lymph nodes examined and outcome in colorectal cancer. Am Surg 75:873-876
4. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK (2004) Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101:3-27
5. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15-18
6. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:777-794
7. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033-1038
8. Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23:289-304
9. Punt CJ, Tol J (2009) More is less-combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 6:731-733
10. Duff SE, Jeziorska M, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC (2007) Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis 9:793-800
11. Royston D, Jackson DG (2009) Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol 217:608-619
12. Sundlisaeter E, Dicko A, Sakariassen PØ, Sondenaa K, Enger PØ, Bjerkvig R (2007) Lymphangiogenesis in colorectal cancer-prognostic and therapeutic aspects. Int J Cancer 121:1401-1409
13. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K (2004) Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95:32-39
14. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O'Dwyer ST, Jayson GC (2003) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89:426-430
15. Achen MG, Mann GB, Stacker SA (2006) Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 94:1355-1360
16. Wissmann C, Detmar M (2006) Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 12:6865-6868
17. Brideau G, Mäkinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T, Heljasvaara R (2007) Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67:11528-11535
18. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S (2005) Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22:31-38
19. Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y (2010) Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 222:249-260
20. Feldman AL, Alexander HR Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, Choyke PL, Libutti SK (2001) A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 8:741-745
21. Chen W, Fu J, Liu Q, Ruan C, Xiao S (2003) Retroviral endostatin gene transfer inhibits human colon cancer cell growth in vivo. Chin Med J (Engl) 116:1582-1584
22. te Velde EA, Reijerkerk A, Brandsma D, Vogten JM, Wu Y, Kranenburg O, Voest EE, Gebbink M, Borel Rinkes IH (2005) Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer 92:729-735
23. Yang L, Wang JW, Sun Y, Zhu YZ, Liu XQ, Li WL (2006) Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 28:138-141
24. Zhang DW, Li HL, Yao Q, Yang WL, Wang HL, Zhai DX, Zhou ZH (2010) The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma. J Int Med Res 38:111-126
25. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21:1323-1360
26. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS (2009) Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 24:995-1003
27. Fujita Y, Abe R, Shimizu H (2008) Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des 14:3820-3834
28. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
29. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
30. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE (2004) Endostatin's antiangiogenic signaling network. Mol Cell 13:649-663
31. Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F (2002) Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 20:184-190
32. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79-84
33. Jenkins DE, Yu SF, Horning YS, Purchio T, Contag PR (2003) In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 20:745-756
34. Lee HY, Choi HJ, Park KJ, Shin JS, Kwon HC, Roh MS, Kim C (2007) Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 14:1712-1717
35. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Role of lymphangiogenesis in cancer. J Clin Oncol 25:4298-4307
36. Thelen A, Scholz A, Benckert C, von Marschall Z, Schröder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S (2008) VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer 122:2471-2481
37. Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K, Stacker SA, Achen MG, Alitalo K, Christofori G (2007) Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol 170:1348-1361